TGFB1 and hepatocellular carcinoma: From a clinical point of view, the qualification criteria for patients set to undergo anti-angiogenic HCC therapy should be more particular and monitored using better methods, especially in those affected by co-existing chronic conditions (e.g., cardiovascular diseases) in which endoglin and TGF-β signalling pathways play a major role.